EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy

Pablo A Palacios iD, Iván Flores, Lucas Cereceda iD, Francisco F Otero, Marioly Müller, Priscilla Brebi iD, Héctor R Contreras iD, Leandro J Carreño

Cancers · 26.01.2025 · 17 (3) · 406

DOI: 10.3390/cancers17030406 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.01.2025. Verfasst von Pablo A Palacios und 7 weiteren Autor:innen. Beteiligte Einrichtung: Millennium Institute on Immunology and Immunotherapy, Programa de Inmunología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FONDECYT, Millennium Institute on Immunology and Immunotherapy ICM-ANID, Center for Cancer Prevention and Control (CECAN)-FONDAP.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Invariant Natural Killer T (iNKT) cells are a unique subset of T cells that bridge innate and adaptive immunity, displaying potent anti-tumor properties through cytokine secretion, direct cytotoxicity, and recruitment of immune effector cells such as CD8+ T cells and NK cells. Despite their therapeutic potential, the immunosuppressive tumor microenvironment (TME), characterized by regulatory T cells, myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), limits iNKT cell efficacy. Patient-derived organoid (PDO) platforms provide an innovative model for dissecting these complex interactions and evaluating strategies to reinvigorate iNKT cell functionality within the TME. PDOs closely mimic the genetic, phenotypic, and structural characteristics of primary tumors, enabling the study of tumor–immune dynamics. Integrating iNKT cells into PDOs offers a robust platform for investigating CD1d-mediated interactions, Th1-biased immune responses driven by glycolipid analogs like α-GalCer, and combination therapies such as immune checkpoint inhibitors. Additionally, PDO systems can assess the effects of metabolic modulation, including reducing lactic acid accumulation or targeting glutamine pathways, on enhancing iNKT cell activity. Emerging innovations, such as organoid-on-a-chip systems, CRISPR-Cas9 gene editing, and multi-omics approaches, further expand the potential of PDO–iNKT platforms for personalized immunotherapy research. Although the application of iNKT cells in PDOs is still undeveloped, these systems hold immense promise for bridging preclinical studies and clinical translation. By addressing the challenges of the TME and optimizing therapeutic strategies, PDO–iNKT platforms offer a transformative avenue for advancing cancer immunotherapy and personalized medicine.

Schlagwörter

Stichwörter der Autor:innen

3D cancer modelsimmunotherapyinvariant Natural Killer T cells (iNKT)patient-derived organoid (PDO)tumor microenvironment (TME)

Autor:innen und Institutionen

  • Millennium Institute on Immunology and Immunotherapy, Programa de Inmunología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.
  • Department of Basic and Clinical Oncology, Faculty of Medicine, Universidad de Chile, Santiago 8350499, Chile.
  • Departamento de Tecnología Médica, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.
  • Millennium Institute on Immunology and Immunotherapy, Laboratory of Integrative Biology (LIBi), Centro de Excelencia en Medicina Traslacional (CEMT), Scientific and Technological Bioresource Nucleus (BIOREN), Universida…
  • Biomedical Research Consortium (BMRC), Santiago 8331150, Chile.
  • Center for Cancer Prevention and Control (CECAN), Santiago 8350499, Chile.

ORCID-Profile: Pablo A Palacios, Lucas Cereceda, Priscilla Brebi, Héctor R Contreras

Förderung

  • FONDECYT
  • Millennium Institute on Immunology and Immunotherapy ICM-ANID
  • Center for Cancer Prevention and Control (CECAN)-FONDAP
  • FONDEF Idea
  • CORFO BMRC, Biomedical research consortium-Chile
  • ANID/Scholarship Program/Doctorado Nacional

Zitieren

APA

Palacios, P. A., Flores, I., Cereceda, L., Otero, F. F., Müller, M., Brebi, P., Contreras, H. R., & Carreño, L. J. (2025). Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy. Cancers, 17(3), 406. https://doi.org/10.3390/cancers17030406

Vancouver

Palacios PA, Flores I, Cereceda L, Otero FF, Müller M, Brebi P, et al. Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy. Cancers. 2025;17(3):406. doi:10.3390/cancers17030406

BibTeX
@article{Palacios2025,
  author = {Palacios, Pablo A and Flores, Iván and Cereceda, Lucas and Otero, Francisco F and Müller, Marioly and Brebi, Priscilla and Contreras, Héctor R and Carreño, Leandro J},
  title = {Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {3},
  pages = {406},
  doi = {10.3390/cancers17030406}
}
Kostenlos starten →